摘要
目的评价沙美特罗/丙酸氟替卡松联合缩唇呼吸治疗尘肺病合并慢性阻塞性肺疾病效果。方法选择2017年2月—2018年4月,呼吸内科收治的尘肺合并COPD患者90例,每入选1例患者便随机分入对照组、观察组。对照组、观察组各入组45例,均给予沙美特罗/丙酸氟替卡松治疗,观察组联合缩唇呼吸治疗,持续12个月。对比治疗前后的疗效、实验室指标。结果治疗后,观察组退出3例、对照组退出5例。治疗后,观察组的FEV1/FVC、6-MWD、血氧饱和度分布为(60.4±9.4)%、(451.6±37.9)m、(95.1±2.3)%高于对照组(51.5±7.1)%、(384.7±80.1)m、(91.0±3.1)%,观察组的CAT评分、TNF-α、CRP分布为(6.8±2.4)分、(84.4±12.5)ng/L、(5.1±2.2)mg/L低于对照组(10.6±2.1)分、(100.8±25.7)ng/L、(7.3±2.9)mg/L,差异有统计学意义(t=4.820、4.871、5.698、7.615、4.132、2.607,P=0.000、0.000、0.000、0.000、0.002、0.011<0.05)。结论沙美特罗/丙酸氟替卡松联合缩唇呼吸治疗尘肺病合并COPD,不仅可以改善肺功能,还可以提升血氧饱和度,减轻炎症。
Objective To evaluate the efficacy of salmeterol/fluticasone propionate combined with lip-reflexion in the treatment of pneumoconiosis with chronic obstructive pulmonary disease. Methods From February 2017 to April 2018,90 patients with pneumoconiosis and COPD were enrolled in the Department of Respiratory Medicine. One patient was randomly assigned to the control group and the observation group. Forty-five patients in the control group and the observation group were treated with salmeterol/fluticasone propionate, and the observation group was treated with lip-reducing respiratory therapy for 12 months. Compare the efficacy and laboratory indicators before and after treatment.Results After treatment, the observation group withdrew 3 cases and the control group withdrew 5 cases. After treatment, the FEV1/FVC, 6-MWD, and oxygen saturation distributions of the observation group were(60.4±9.4)%,(451.6±37.9)m,(95.1±2.3)% higher than the control group(51.5±7.1)%,(384.7±80.1)m,(91.0±3.1)%, the CAT score, TNF-α,CRP distribution of the observation group were(6.8±2.4)points,(84.4±12.5)ng/L,(5.1±2.2)mg/L was lower than the control group(10.6±2.1)points,(100.8±25.7)ng/L,(7.3±2.9)mg/L, the difference was statistically significant(t=4.820, 4.871,5.698, 7.615, 4.132, 4.607, P=0.000, 0.000, 0.000, 0.000, 0.002, 0.011<0.05). Conclusion Salmeterol/fluticasone propionate combined with lip-reducing pneumoconiosis combined with COPD can not only improve lung function, but also improve blood oxygen saturation and reduce inflammation.
作者
康晓达
KANG Xiao-da(Department of Respiratory and Critical Care Medicine,First People's Hospital of Honghe Prefecture,Honghe,Yunnan Province,661100 China)
出处
《系统医学》
2019年第7期137-138,174,共3页
Systems Medicine
关键词
尘肺
慢性阻塞性肺疾病
缩唇呼吸
沙美特罗/丙酸氟替卡松
Pneumoconiosis
Chronic obstructive pulmonary disease
Lip gas respiration
Salmeterol / fluticasone propionate
作者简介
康晓达(1979-),男,云南建水人,本科,副主任医师,研究方向:呼吸与危重症医学科.
